SEC and FDA Sign MOU to Sharpen Oversight on Food, Drug Disclosures
SEC and FDA agreed on a three-year MOU to share regulatory data for enforcement.
Why it matters: Legal and compliance teams must brace for increased SEC scrutiny using FDA data to detect misleading corporate disclosures related to drugs and food products.
- The MOU, signed August 31, 2026, commits SEC and FDA to share information for at least three years.
- SEC will access confidential FDA data like product reviews and clinical trial info to support investigations.
- This partnership targets false or misleading investor disclosures about FDA approvals and regulatory status.
- SEC Enforcement Director Stephen M. Cutler highlighted FDA’s strong interest in coordinated enforcement efforts.
On August 31, 2026, the U.S. Securities and Exchange Commission (SEC) and the U.S. Food and Drug Administration (FDA) formalized a memorandum of understanding (MOU) designed to increase regulatory cooperation. The agreement creates a framework for sharing confidential FDA data related to food and drug products with the SEC to improve enforcement.
Under this pact, effective for a minimum of three years, the SEC gains access to nonpublic FDA information, such as ongoing product reviews and clinical trial results. This data will help the SEC investigate companies that might make false or misleading statements to investors about FDA approvals or regulatory developments.
"The Commission staff appreciates FDA's strong interest in coordinating our agencies' activities in a cooperative manner," said Stephen M. Cutler, Director of the SEC's Division of Enforcement. This reflects an increased focus on protecting investors by verifying the truthfulness of corporate disclosures backed by FDA oversight.
The FDA emphasized that the MOU also enhances public health protections by promoting accurate information disclosure about medical products regulated by the FDA.
For legal and compliance professionals, this means heightened SEC investigations relying on FDA data to detect inaccurate or incomplete disclosures in public filings. The term "nonpublic information" here means confidential agency data not publicly available, such as proprietary trial data or product evaluations. "False investor disclosures" refer to misleading or untrue statements companies make that could affect investment decisions.
While the precise operational details will remain confidential, this collaboration marks a significant shift toward integrated federal enforcement, requiring corporate compliance teams to strengthen review processes to manage related risks.
By the numbers:
- 3 years — duration of the SEC-FDA MOU cooperation
- August 31, 2026 — date the MOU was signed
Yes, but: The MOU’s operational specifics and exact data-sharing protocols remain confidential, leaving some uncertainty about how investigations will proceed in practice.
What's next: Legal and compliance teams should monitor future SEC and FDA guidance clarifying procedures for information sharing and enforcement actions under the MOU.